Papers/PMID:41628126
Iodine increases pulmonary type I interferon responses and decreases covid-19 disease severity: Results from an open label randomized clinical trial.
PloS one2026The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
iodide — decreases intensive care unit length of stay
Evidence strength: moderate.Finding“In which the patients that received iodine (8.33 days S.D. 5.5, n = 7) had a significantly shorter stay on the ICU compared to the standard of care group (26.5 days S.D. 19, n = 11) (Fig 2).”
Quoted verbatim from Iodine increases pulmonary type I interferon responses and decreases covid-19 disease severity: Results from an open label randomized clinical trial.. - Study
- RCT
- Duration
- 8 days
- Dose
- 12.5 mg iodine as potassium iodide tablets once daily for 8 days
- Population
- Adults hospitalised with PCR-confirmed COVID-19 in a Dutch community hospital, all on standard care; only the subset who were admitted to the ICU (7 iodine, 11 control), analysed after randomisation; open-label, no placebo
Iodine increases pulmonary type I interferon responses and decreases covid-19 disease severity: Results from an open label randomized clinical trial.2026PMID:4162812610.1371/journal.pone.0341126Permalink